NIGHTHAWK

NETGEAR Unveils Next Generation of Connectivity with the Nighthawk DOCSIS 3.1 High-Speed Internet Cable Modem

Retrieved on: 
Tuesday, March 12, 2024
Consumer Electronics, Technology, Other Technology, Networks, Internet, Hardware, Bit, NETGEAR, Modem, ISP, Comcast, DOCSIS 3.1, NAS, Wi-Fi, Internet service provider, Zoom, Data-rate units, Ecosystem, Cox, Music, Multimedia, OpenVault, Cable television

NETGEAR®, Inc. (NASDAQ: NTGR), the leading provider of networking products that power both home and office, today announced the availability of the next-generation Nighthawk® DOCSIS® 3.1 High-Speed Internet Cable Modem (CM3000) , specifically engineered to handle today’s fastest DOCSIS 3.1 cable internet speeds that can only be accessed with mid/high-split technology.

Key Points: 
  • NETGEAR®, Inc. (NASDAQ: NTGR), the leading provider of networking products that power both home and office, today announced the availability of the next-generation Nighthawk® DOCSIS® 3.1 High-Speed Internet Cable Modem (CM3000) , specifically engineered to handle today’s fastest DOCSIS 3.1 cable internet speeds that can only be accessed with mid/high-split technology.
  • View the full release here: https://www.businesswire.com/news/home/20240312800246/en/
    NETGEAR unveils the next generation of connectivity with the Nighthawk DOCSIS 3.1 High-Speed Internet Cable Modem (CM3000).
  • The stylish, mid/high-split Nighthawk CM3000 cable modem works seamlessly with these and every other major U.S. cable service provider and is future-proofed for the even more demanding high-split needs to come.
  • Or reach up to 2Gbps by connecting the two Gigabit ports to a router that supports Internet with link aggregation.

Moneta Gold and Nighthawk Gold Announce the Proposed Directors for the MergeCo Board

Retrieved on: 
Monday, January 22, 2024
Mining, Minerals, Natural Resources, Diamond, Senior, Mitel, TMX Group, General counsel, Labrador Iron Mines, Research, Kinross Gold, Sustainability, Quadra FNX Mining, Foreign policy, CFO, Kirkland Lake Gold, ESG, Staples Inc., National Bank of Canada, TSX, Eldorado Gold, TD Securities, Communication, Osisko Gold Royalties, SVP

He was the VP Corporate Development & Technical Services for Kirkland Lake Gold, where he led the due diligence and execution of the merger with Newmarket Gold.

Key Points: 
  • He was the VP Corporate Development & Technical Services for Kirkland Lake Gold, where he led the due diligence and execution of the merger with Newmarket Gold.
  • Mr. Salehi also had management roles with St. Andrew Goldfields, Lake Shore Gold, FNX Mining, and Vale.
  • She is currently the SVP, Investor Relations & Communications for Galiano Gold and a director of Ensign Minerals.
  • Previously, she served as SVP, External Affairs and Sustainability for Eldorado Gold Corporation.

Independent Proxy Advisor Firm ISS Recommends Nighthawk Shareholders Vote FOR Transaction with Moneta Gold; Nighthawk Gold Provides Supplemental Disclosure in respect of the Transaction with Moneta Gold

Retrieved on: 
Thursday, January 18, 2024
Natural Resources, Other Natural Resources, Mining, Minerals, Circular, Person, Transaction, NHK, Meeting, TSX, Acceleration, Minority, Disclosure, Institutional Shareholder Services, Security (finance)

The Company also wishes to provide the following additional disclosure to supplement the disclosure in the joint management information circular (the “Circular”) for the Meetings in connection with the Transaction.

Key Points: 
  • The Company also wishes to provide the following additional disclosure to supplement the disclosure in the joint management information circular (the “Circular”) for the Meetings in connection with the Transaction.
  • Capitalized terms not otherwise defined below shall have the meanings ascribed to such terms in the Circular.
  • The Company is subject to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”).
  • Therefore, as a result of this determination, the resolution of shareholders of the Company approving the Transaction will not require “minority approval” in accordance with MI 61-101.

NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

Retrieved on: 
Tuesday, January 16, 2024
Scorpius, Life, Fermentation, Laboratory, CDMO, Annual report, Pharmaceutical industry

The initial project value exceeds one million dollars, with the potential to exceed several million dollars over the next two years.

Key Points: 
  • The initial project value exceeds one million dollars, with the potential to exceed several million dollars over the next two years.
  • This award reflects our growing reputation in the industry, as well as our track record advancing early stage clinical programs.
  • Scorpius offers a broad array analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX.
  • With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

Retrieved on: 
Monday, January 8, 2024
Marketing, Associate, PEGylation, Commercial, Biotechnology, Spacecraft, Pennsylvania State University, Quality management system, Binghamton University, Ania, Control, Technology transfer, Annual report, Robert Morris University, CMC, Lehigh University, University, Region, Doctor of Philosophy, Therapy, Scorpius, PPQ, Patheon, Chemical engineering, Rutgers University, Computer science, Biochemical engineering, Research, GMP, WuXi AppTec, Business development, Quality assurance, Growth, Investment, Bristol Myers Squibb

The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.

Key Points: 
  • The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.
  • Jeff Wolf, CEO of Nighthawk, commented, “Our rebranding to Scorpius Holdings is a testament to our successful transition and the growth of our CDMO operations.
  • The industry faces a critical shortage of clinical-scale biologic manufacturing capacity, driven by increasing demand for large molecule CDMO services.
  • Our state-of-the-art facility in San Antonio, Texas ideally positions us to address this gap in CDMO manufacturing capacity and services.

NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University

Retrieved on: 
Wednesday, January 3, 2024
Opioid, Annual report, University, Research, CDMO, Importance, Traction, Scorpius, Pharmaceutical industry

Jeff Wolf, CEO of NightHawk, commented, “We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States.

Key Points: 
  • Jeff Wolf, CEO of NightHawk, commented, “We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States.
  • Scorpius was selected due to its process development and large molecule manufacturing expertise, as well as its flexibility and dedication to customer service.
  • We are off to a strong start and look forward to expanding this relationship into additional programs in 2024 and beyond.
  • Scorpius offers a broad array analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the art facilities in San Antonio, TX.

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

Retrieved on: 
Thursday, December 21, 2023
Work, Annual report, Research, CDMO, DTRA, Defense Threat Reduction Agency, Growth, NIH, Scorpius

DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary (“Scorpius”) completed a demonstration run in the Company’s process development lab for a microbial vaccine program developed by a top-tier research university that is NIH and DTRA (Defense Threat Reduction Agency) funded.

Key Points: 
  • Jeff Wolf, CEO of NightHawk, commented, “This first phase of a multi-million-dollar project was particularly noteworthy, as we achieved a successful demonstration run following a prior failed attempt by a competitor CDMO.
  • The complexity of the project led this top-tier university to choose Scorpius, drawn by our more engaged management approach and accelerated development timeline.
  • The successful completion of this demonstration run showcases our team's dedication and expertise, and represents an important step in advancing our relationship with this nationally renowned university.
  • The next phase of this project will include scaling up to cGMP manufacturing to support a phase 1 infectious disease trial.

NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company

Retrieved on: 
Monday, December 18, 2023
Work, Annual report, Government, CDMO, Growth, Patient

DURHAM, N.C., Dec. 18, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary initiated its first manufacturing run for a premier U.S.-based biopharmaceutical company in the Company’s new, state-of-the-art microbial manufacturing facility.

Key Points: 
  • Advances multi-million dollar biomanufacturing contract awarded earlier this year;
    DURHAM, N.C., Dec. 18, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary initiated its first manufacturing run for a premier U.S.-based biopharmaceutical company in the Company’s new, state-of-the-art microbial manufacturing facility.
  • Jeff Wolf, CEO of NightHawk, commented, “We are generating strong interest in our CDMO services, given our state-of-the-art facility and the industry-wide lack of available capacity for large molecule manufacturing.
  • This demonstration run in our new microbial facility marks a major milestone, as it represents the first at-scale production run with a premier biopharmaceutical company and reflects positively upon our manufacturing readiness, as well as our ability to meet their stringent product requirements.
  • Importantly, this milestone enables us to build upon the initial multi-million-dollar contract with this client, which we expect to recognize as revenue during 2024.

NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets

Retrieved on: 
Tuesday, December 12, 2023
Annual report, Research, CDMO, Growth, Scorpius, Fine chemical

DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) today (“NightHawk” or the “Company”) announced its strategic shift into a pure-play biomanufacturing Contract Development & Manufacturing Organization (CDMO), as well as the divestiture of certain non-core assets, in order to focus on the growing sales within its Scorpius BioManufacturing subsidiary (“Scorpius”). The Company has booked contracts thus far in 2023, Scorpius’ first full year of operation, that are expected to generate over $20 million in revenue, a substantial portion of which will be recognized in 2024. To facilitate this strategic shift, the Company has divested its Elusys subsidiary and related assets, and has eliminated most of its R&D and associated expenses to focus its resources on growing and expanding Scorpius.

Key Points: 
  • The assets will be acquired by a private company established by Jeff Wolf, CEO of NightHawk, which will assume Elusys’ contracted financial commitments, currently estimated at over $40 million.
  • The royalties are subject to a mandatory minimum payment of $5 million during the first five years of the royalty term.
  • Scorpius booked $3 million in contracted sales in 2022, which has grown to over $20 million in contracted sales thus far in 2023.
  • With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.

NightHawk Biosciences Provides Q3 2023 Business Update

Retrieved on: 
Monday, November 20, 2023
Marketing, Depreciation, Ecosystem, Form 10-K, Annual report, Sale, Drug development, Software, Research, CDMO, Therapy, Clinical trial, Insurance, Elusys Therapeutics, Investment, Growth, Scorpius, Life, Pharmaceutical industry

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023.

Key Points: 
  • DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023.
  • As a result, we are currently evaluating a variety of strategic options to maximize the potential of the business.
  • Selling, general and administrative expenses were $6.1 million and $4.8 million for the three months ended September 30, 2023 and 2022, respectively.
  • NightHawk Biosciences leverages its integrated ecosystem of subsidiaries to streamline the advancement of novel therapies, breaking through barriers that prolong traditional drug development.